Plain-English translation of NCT07536061 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Huntington's Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medicine called for people with Huntington's disease. Researchers want to learn if the medication is safe, what the right dose should be, and whether it helps slow or manage this genetic condition. This is the first time this treatment is being tested in humans.
Huntington's disease is a progressive neurological condition caused by a genetic mutation that affects movement, thinking, and mood. Currently, there are limited treatment options, and this trial is exploring whether this new medication might help by lowering levels of the harmful huntingtin protein.
You likely qualify if…
You likely don't qualify if…
Participants will be divided into four groups, each receiving a different dose of or a placebo (inactive treatment). Half of each group receives the medication and half receives placebo, but neither participants nor researchers know who gets which. Over the course of the study, you'll attend multiple visits involving physical exams, blood draws, spinal taps, brain imaging (MRI), and assessments of your symptoms.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
Australia
New Zealand
Switzerland
United Kingdom